Horizon Therapeutics PLC (HZNP): Price and Financial Metrics


Horizon Therapeutics PLC (HZNP): $78.00

-0.28 (-0.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HZNP POWR Grades

  • Value is the dimension where HZNP ranks best; there it ranks ahead of 92.31% of US stocks.
  • The strongest trend for HZNP is in Momentum, which has been heading up over the past 178 days.
  • HZNP's current lowest rank is in the Momentum metric (where it is better than 24.4% of US stocks).

HZNP Stock Summary

  • HORIZON THERAPEUTICS PUBLIC LTD CO's market capitalization of $17,569,962,181 is ahead of 88.94% of US-listed equities.
  • With a one year PEG ratio of 141.89, HORIZON THERAPEUTICS PUBLIC LTD CO is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 84.18% of US stocks.
  • HZNP's current price/earnings ratio is 30.6, which is higher than 78.27% of US stocks with positive earnings.
  • Stocks that are quantitatively similar to HZNP, based on their financial statements, market capitalization, and price volatility, are TECH, APPS, MASI, OSIS, and PRLB.
  • HZNP's SEC filings can be seen here. And to visit HORIZON THERAPEUTICS PUBLIC LTD CO's official web site, go to www.horizontherapeutics.com.

HZNP Valuation Summary

  • In comparison to the median Healthcare stock, HZNP's price/sales ratio is 140% higher, now standing at 4.8.
  • Over the past 138 months, HZNP's price/earnings ratio has gone up 34.8.

Below are key valuation metrics over time for HZNP.

Stock Date P/S P/B P/E EV/EBIT
HZNP 2022-11-25 4.8 3.5 30.9 27.1
HZNP 2022-11-23 4.7 3.5 30.6 26.8
HZNP 2022-11-22 4.7 3.5 30.5 26.7
HZNP 2022-11-21 4.7 3.5 30.3 26.6
HZNP 2022-11-18 4.7 3.4 30.1 26.4
HZNP 2022-11-17 4.6 3.4 29.6 26.0

HZNP Growth Metrics

    Its 3 year price growth rate is now at 238.06%.
  • Its year over year net income to common stockholders growth rate is now at 207.85%.
  • The 2 year price growth rate now stands at 124.58%.
HZNP's revenue has moved up $2,401,450,000 over the prior 33 months.

The table below shows HZNP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3,701.479 1,370.008 574.256
2022-06-30 3,813.112 1,414.584 764.96
2022-03-31 3,769.249 1,254.79 862.103
2021-12-31 3,226.41 1,035.271 534.491
2021-09-30 2,957.26 906.531 551.866
2021-06-30 2,556.695 604.354 518.163

HZNP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HZNP has a Quality Grade of C, ranking ahead of 61.77% of graded US stocks.
  • HZNP's asset turnover comes in at 0.385 -- ranking 123rd of 681 Pharmaceutical Products stocks.
  • VNDA, NEOG, and CEMI are the stocks whose asset turnover ratios are most correlated with HZNP.

The table below shows HZNP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.385 0.758 0.134
2021-06-30 0.367 0.759 0.130
2021-03-31 0.361 0.755 0.125
2020-12-31 0.425 0.758 0.237
2020-09-30 0.382 0.744 0.142
2020-06-30 0.357 0.734 0.038

HZNP Price Target

For more insight on analysts targets of HZNP, see our HZNP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $132.84 Average Broker Recommendation 1.33 (Strong Buy)

HZNP Stock Price Chart Interactive Chart >

Price chart for HZNP

HZNP Price/Volume Stats

Current price $78.00 52-week high $117.49
Prev. close $78.28 52-week low $57.84
Day low $77.71 Volume 1,791,200
Day high $79.46 Avg. volume 2,255,129
50-day MA $68.11 Dividend yield N/A
200-day MA $82.75 Market Cap 17.68B

Horizon Therapeutics PLC (HZNP) Company Bio


Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. (Source:Wikipedia)


HZNP Latest News Stream


Event/Time News Detail
Loading, please wait...

HZNP Latest Social Stream


Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about HORIZON THERAPEUTICS PUBLIC LTD CO that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon Therapeutics (HZNP) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Yahoo | November 23, 2022

15 Biggest European Pharmaceutical Companies

In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […]

Yahoo | November 23, 2022

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

DUBLIN, November 16, 2022--Horizon announced that enrollment of its Phase 3 clinical trial (OPTIC-J) in Japan evaluating TEPEZZA for the treatment of active TED is complete.

Yahoo | November 16, 2022

Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation

DUBLIN, November 16, 2022--Horizon Therapeutics plc today announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop therapies for patients with serious autoimmune and inflammatory conditions. The initial focus is the emerging field of immunometabolism, the study of metabolic processes in the body, that when dysregulated, can drive autoimmunity and inflammation. This is the first project in the

Yahoo | November 16, 2022

Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November

DUBLIN, November 10, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November:

Yahoo | November 10, 2022

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo 22.20%
3-mo 32.38%
6-mo -12.84%
1-year -25.36%
3-year 137.95%
5-year 466.45%
YTD -27.62%
2021 47.31%
2020 102.07%
2019 85.26%
2018 33.84%
2017 -9.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6241 seconds.